Organizations
Conferences
Info & Opinion
October 12, 2008
Highlights from a recent Center for Business Intelligence conference on patient reported outcomes.
Cytel and Tourtellotte Consulting join forces to design trials and drug supply needs for adaptive protocols.
An article in the Harvard Business Review in February 2007 outlines the mistakes of companies that do not engage the media, and offers a prescription for regaining a good public image.
The most notable nugget from the Center for Business Intelligence’s (CBI) Arlington, Virginia meeting on patient-reported outcome (PRO) research late last month was not so much from the podium, though there was plenty of excellent material there. Some of the…
The math of adaptive trials is hairy. But the appeal is simple. Adaptive trials can reveal the optimal dose in a single trial—not six. They can identify dud drugs early. The approach can require significantly smaller sample sizes and save…
We’ve been as surprised as anyone by the Wall Street Journal’s running baseball-style scorecards showing how many lawsuits Merck has won, lost and tied. It’s notable. Merck is using a starkly different strategy than the one that was popular not…